Often, my job of finding emerging profit trends means discovering exciting new technologies or getting out in front of a big trade.
But there’s a lot I do that might not seem as exciting as all that. For instance, to get out in front of emerging trends, I must follow them for months before they even become available to investors.
The emerging psychedelic medical treatment industry is one such trend.
Last year, I wrote about how big of an idea this could become. Not only were there ongoing FDA clinical trials for psychedelic and psilocybin therapies. A few companies have even found their way onto the stock market.
But so much can change when a trend is this hot in such a short amount of time.
And with change, now finally comes real, tangible opportunity.
The State of the Psychedelic Industry
Backing up, in case you haven’t been privy to this huge potential market, scientists have found that psychedelics from magic mushrooms to LSD actually have several beneficial effects on a number of problems.
Studies dating back a decade have found that small doses, or microdoses, of these substances can actually help ease depression, symptoms of PTSD and even adult ADHD.
Obviously, a doctor can’t just prescribe their patients take mushrooms as if they were Advil. But as more studies emerge, psychedelic treatments continue to gain clinical acceptance, especially in cases where nothing else has worked.
Some areas, like Denver, CO and the state of Oregon have already decriminalized these drugs both for medical research reasons as well as the nationwide push for limited incarceration for nonviolent crimes.
More should catch on. Remember, these are the places where cannabis legalization got its roots in this country. And look at what’s happened to that industry.
Of course, the last time I wrote about this wild breakthrough industry there were only a few small ways to even consider getting in.
Over just the last two months, the number of available investments in this space has just about doubled.
And as these investments hit the big stage, you now finally have a chance to act.
5 Initial Plays Kick Off Multibillion Industry
As you can imagine, a lot of research into this transformative industry is done through academia and private labs with limited government approval.
But the market does seem to have moved the goalposts on how research of this scale takes place.
When I last wrote about this, there were basically two companies involved in the medical side and one sort of with a hand in everything else.
Now, with the dawn of a new year and new administration, more have jumped in. And so far, they are all progressing faster than anyone could have believed.
Champignon Brands Inc. (OTC: SHRMF) — The “conglomerate” approach. It has its hands in everything from growing mushrooms to ramping up the supply chain to researchers.
COMPASS Pathways plc (NASDAQ: CMPS) — The first major drug developer to market and the first to jump onto a major exchange.
Mind Medicine (MindMed) Inc. (OTC: MMEDF) — The second in everything, so far. Second to market, second set to jump to the Nasdaq and second in size. But not necessarily the second most-profitable opportunity.
Cybin Inc. (OTC: CLXPF) — A Toronto-based drug developer that just began trading two months ago with an additional business in non-psychedelic medical mushrooms.
Mydecine Innovations Group Inc. (OTC: MYCOF) — The last, and smallest of the drug developers here with a market cap of just $70 million.
The four drug developers here are all in Phase 2 clinical trials with the FDA. That’s probably further along than almost anyone seems to be aware of.
With the largest of these plays coming in at a market value of just $1.6 billion, there’re still huge opportunities here… in all five.
As you can see, since I last wrote about this industry and since the last election, investors have really started heating up to this idea.
That’s not going to stop any time soon.
As marijuana continues to inch closer to a national decriminalization and eventual legalization, don’t discount this other industry. Starting smaller, it has room to grow even faster.
This might be the last great entry point of the year. Though, I expect turnover and change to continue to be factors as it evolves.
For now, this is one emerging profit opportunity that’s definitely moved from “watch it” to “buy it.”
To your prosperity and health,
Joshua M. Belanger
Joshua M. Belanger
Joshua Belanger is founder of CounterVest and the editor of Hot Money Trader. He has been providing ordinary investors blockbuster returns since 2008. In 2018, the average return of Hot Money Trader beat the markets by over 15%
Subscribe to Emerging Profits Daily for FREE.
Receive today's top emerging opportunities for tomorrow's profits delivered straight to your inbox.